《新股消息》博安生物-B(06955.HK)公開發售定價19.8元 一手中籤率近44%
綠葉製藥(02186.HK)分拆的綜合性生物製藥商博安生物-B(06955.HK)公布招股結果,每股發售價定為19.8元,香港公開發售部分錄得超額認購約1.12倍。每手200股計,一手中籤率約43.84%,認購3手穩獲一手。該股將於明日(30日)掛牌。聯席保薦人為瑞銀集團及安信國際。
公司上市引入3名基石投資者,包括艾迪藥業(688488.SH)創辦人傅和亮、Harvest及中生製藥(01177.HK),合共認購約759.4萬股公司股份,佔緊隨全球發售完成後已發行股本約1.49%。
此外,公司上市料淨集資約1.53億元,當中約59.5%將用於公司核心產品的研發;約31.4%將用於公司管線中其他產品的研發;約6.1%將用於商業化目的;約3%將用於營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.